GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Supernus Pharmaceuticals SUPN · USD

Health Care · US listing · 🇺🇸 United States

Compare

27.62

+5.58%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

11 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 3Strong buy
  • 6Buy
  • 2Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Low
65.00
Average
65.00
Median
65.00
High
65.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$884.4m$1.46bn$1.88bn$2.04bn$2.14bn
Revenue, highest$894.6m$1.48bn$1.95bn$2.06bn$2.16bn
Revenue, lowest$873.8m$1.45bn$1.81bn$2.02bn$2.11bn
Earnings per share2.774.185.205.705.85
Earnings per share, highest2.804.406.565.795.94
Earnings per share, lowest2.723.973.845.615.76
Analysts22211

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Forecast1.060.420.300.350.600.480.380.42
Reported1.320.540.600.841.010.900.440.75
Difference+24.5%+27.8%+97.7%+142.2%+67.8%+87.7%+15.5%+77.2%

Rating changes

Latest broker notes

  • Cantor FitzgeraldOverweight
  • StifelHold
  • TD CowenBuy
  • Piper SandlerNeutral → Overweight
  • Cantor FitzgeraldOverweight
  • Piper SandlerNeutral
  • Cantor FitzgeraldOverweight
  • Cantor FitzgeraldNeutral
  • Cantor FitzgeraldOverweight → Neutral

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

4 / 10

Revenue growth 17.4% a year over 10 years. Return on equity -3.6%.

Model fair value

106.21

From earnings 106.21, from revenue 43.40.

Piotroski score

4 / 9

A nine-point test of financial strength, for 31 Dec 2024.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.